WallStSmart

Johnson Controls International PLC (JCI)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson Controls International PLC generates 659% more annual revenue ($24.43B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 14.4%. JCI appears more attractively valued with a PEG of 1.98. WST earns a higher WallStSmart Score of 65/100 (C+).

JCI

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 7.0Value: 4.3Quality: 5.0
Piotroski: 5/9Altman Z: 1.11

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JCI.

WSTSignificantly Overvalued (-55.4%)

Margin of Safety

-55.4%

Fair Value

$158.40

Current Price

$314.50

$156.10 premium

UndervaluedFair: $158.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JCI3 strengths · Avg: 8.7/10
Market CapQuality
$89.11B9/10

Large-cap with strong market position

Return on EquityProfitability
26.1%9/10

Every $100 of equity generates 26 in profit

EPS GrowthGrowth
38.9%8/10

Earnings expanding 38.9% YoY

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

JCI3 concerns · Avg: 2.7/10
PEG RatioValuation
1.984/10

Expensive relative to growth rate

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.112/10

Distress zone — elevated risk

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : JCI

The strongest argument for JCI centers on Market Cap, Return on Equity, EPS Growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : JCI

The primary concerns for JCI are PEG Ratio, P/E Ratio, Altman Z-Score. A P/E of 44.7x leaves little room for execution misses.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

JCI profiles as a value stock while WST is a growth play — different risk/reward profiles.

JCI carries more volatility with a beta of 1.34 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

JCI generates stronger free cash flow (604M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 59/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson Controls International PLC

INDUSTRIALS · BUILDING PRODUCTS & EQUIPMENT · USA

Johnson Controls International plc is an Irish-domiciled multinational conglomerate headquartered in Cork, Ireland, that produces fire, HVAC, and security equipment for buildings.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?